CHF97.60
0.93% today
SIX Swiss Exchange, Sep 19, 11:13 am CET
ISIN
CH0012005267
Symbol
NOVN

Novartis Stock price

CHF96.70
-3.52 3.51% 1M
-1.73 1.76% 6M
+8.00 9.02% YTD
-1.34 1.37% 1Y
+24.00 33.02% 3Y
+19.09 24.60% 5Y
+19.48 25.22% 10Y
+45.04 87.18% 20Y
SIX Swiss Exchange, Closing price Thu, Sep 18 2025
+0.12 0.12%
ISIN
CH0012005267
Symbol
NOVN
Industry

Key metrics

Basic
Market capitalization
CHF183.8b
Enterprise Value
CHF204.1b
Net debt
CHF20.3b
Cash
CHF5.3b
Shares outstanding
1.9b
Valuation (TTM | estimate)
P/E
17.5 | 13.4
P/S
4.2 | 4.1
EV/Sales
4.7 | 4.6
EV/FCF
15.3
P/B
5.5
Dividends
DPS
CHF3.50
Yield 1Y | 5Y
3.6% | 3.8%
Growth 1Y | 5Y
6.1% | 4.9%
Payout 1Y | 3Y
75.3% | 76.7%
Increased
25 Years
Financials (TTM | estimate)
Revenue
CHF43.5b | CHF44.7b
EBITDA
CHF14.7b | CHF18.0b
EBIT
CHF14.5b | CHF16.6b
Net Income
CHF10.8b | CHF13.9b
Free Cash Flow
CHF13.3b
Growth (TTM | estimate)
Revenue
12.2% | 9.0%
EBITDA
45.4% | 37.1%
EBIT
44.8% | 28.6%
Net Income
-15.6% | 47.2%
Free Cash Flow
41.3%
Margin (TTM | estimate)
Gross
76.1%
EBITDA
33.9% | 40.2%
EBIT
33.5%
Net
24.9% | 31.2%
Free Cash Flow
30.6%
Financial Health
Equity Ratio
43.1%
Return on Equity
27.1%
ROCE
25.2%
ROIC
21.6%
Debt/Equity
0.8
More
EPS
CHF5.5
FCF per Share
CHF6.9
Short interest
-
Employees
76k
Rev per Employee
CHF540.0k
Show more

Create a Free Account to create an Novartis alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Novartis Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Novartis forecast:

13x Buy
42%
15x Hold
48%
3x Sell
10%

Analyst Opinions

31 Analysts have issued a Novartis forecast:

Buy
42%
Hold
48%
Sell
10%

Financial data from Novartis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
43,466 43,466
12% 12%
100%
- Direct Costs 10,381 10,381
6% 6%
24%
33,085 33,085
14% 14%
76%
- Selling and Administrative Expenses 10,408 10,408
5% 5%
24%
- Research and Development Expense 7,670 7,670
9% 9%
18%
14,748 14,748
45% 45%
34%
- Depreciation and Amortization 208 208
115% 115%
0%
EBIT (Operating Income) EBIT 14,540 14,540
45% 45%
33%
Net Profit 10,822 10,822
16% 16%
25%

In millions CHF.

Don't miss a Thing! We will send you all news about Novartis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis Stock News

AD HOC NEWS
7 days ago
Die US-Investmentbank Goldman Sachs hat Novartis CH0012005267 von "Neutral" auf "Sell" abgestuft und das Kursziel von 95 auf 94 Franken gesenkt.
AD HOC NEWS
29 days ago
Deutsche Bank Research hat das Kursziel für Novartis CH0012005267 von 115 auf 120 Franken angehoben und die Einstufung auf "Buy" belassen.
AD HOC NEWS
about 2 months ago
Das US-Analysehaus Bernstein Research hat die Einstufung für Novartis CH0012005267 auf "Outperform" mit einem Kursziel von 108 Franken belassen.
More Novartis News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 75,883
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today